The effects of different periods of co-administration of oral and long-acting injectable aripiprazole: A propensity score analysis

Masakazu Hatano, Hiroyuki Kamei, Ippei Takeuchi, Kaori Tozawa, Shinya Makino, Manako Hanya, Shigeki Yamada, Nakao Iwata

研究成果: Article

抄録

Objective: Long-acting injectable (LAI) aripiprazole is recommended to be combined with oral aripiprazole for 2 weeks after its introduction. However, we often experience patients who require more than 2 weeks of combined use. Therefore, differences in combination periods need to be examined. Methods: This was a case–control study. We surveyed prescription profiles for oral aripiprazole administration in conjunction with LAI aripiprazole introduction and assessed the clinical course during a 12-week follow-up period. Results: Among 121 patients, 58 (47.9%) were administered both oral and LAI aripiprazole for more than 2 weeks. Although there was no significant difference in treatment failure (defined as psychiatric hospitalization or discontinuation of LAI aripiprazole from any cause) between the two groups, the group that was administered oral aripiprazole for more than 2 weeks received less additional benzodiazepines compared with that of the 2 weeks group (adjusted odds ratio, 0.055; 95% confidence interval [0.0060, 0.50]; p < 0.01). Conclusions: Our data support a flexible co-administration period for oral and LAI aripiprazole in consideration of the pharmacokinetics, but further studies are needed.

元の言語English
記事番号e2681
ジャーナルHuman Psychopharmacology
34
発行部数1
DOI
出版物ステータスPublished - 01-2019

Fingerprint

Propensity Score
Oral Administration
Injections
Aripiprazole
Treatment Failure
Benzodiazepines
Prescriptions
Psychiatry
Hospitalization
Pharmacokinetics
Odds Ratio
Confidence Intervals

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

これを引用

Hatano, Masakazu ; Kamei, Hiroyuki ; Takeuchi, Ippei ; Tozawa, Kaori ; Makino, Shinya ; Hanya, Manako ; Yamada, Shigeki ; Iwata, Nakao. / The effects of different periods of co-administration of oral and long-acting injectable aripiprazole : A propensity score analysis. :: Human Psychopharmacology. 2019 ; 巻 34, 番号 1.
@article{da368de5c80e49c2bcd79a0eb98feed1,
title = "The effects of different periods of co-administration of oral and long-acting injectable aripiprazole: A propensity score analysis",
abstract = "Objective: Long-acting injectable (LAI) aripiprazole is recommended to be combined with oral aripiprazole for 2 weeks after its introduction. However, we often experience patients who require more than 2 weeks of combined use. Therefore, differences in combination periods need to be examined. Methods: This was a case–control study. We surveyed prescription profiles for oral aripiprazole administration in conjunction with LAI aripiprazole introduction and assessed the clinical course during a 12-week follow-up period. Results: Among 121 patients, 58 (47.9{\%}) were administered both oral and LAI aripiprazole for more than 2 weeks. Although there was no significant difference in treatment failure (defined as psychiatric hospitalization or discontinuation of LAI aripiprazole from any cause) between the two groups, the group that was administered oral aripiprazole for more than 2 weeks received less additional benzodiazepines compared with that of the 2 weeks group (adjusted odds ratio, 0.055; 95{\%} confidence interval [0.0060, 0.50]; p < 0.01). Conclusions: Our data support a flexible co-administration period for oral and LAI aripiprazole in consideration of the pharmacokinetics, but further studies are needed.",
author = "Masakazu Hatano and Hiroyuki Kamei and Ippei Takeuchi and Kaori Tozawa and Shinya Makino and Manako Hanya and Shigeki Yamada and Nakao Iwata",
year = "2019",
month = "1",
doi = "10.1002/hup.2681",
language = "English",
volume = "34",
journal = "Human Psychopharmacology",
issn = "0885-6222",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

The effects of different periods of co-administration of oral and long-acting injectable aripiprazole : A propensity score analysis. / Hatano, Masakazu; Kamei, Hiroyuki; Takeuchi, Ippei; Tozawa, Kaori; Makino, Shinya; Hanya, Manako; Yamada, Shigeki; Iwata, Nakao.

:: Human Psychopharmacology, 巻 34, 番号 1, e2681, 01.2019.

研究成果: Article

TY - JOUR

T1 - The effects of different periods of co-administration of oral and long-acting injectable aripiprazole

T2 - A propensity score analysis

AU - Hatano, Masakazu

AU - Kamei, Hiroyuki

AU - Takeuchi, Ippei

AU - Tozawa, Kaori

AU - Makino, Shinya

AU - Hanya, Manako

AU - Yamada, Shigeki

AU - Iwata, Nakao

PY - 2019/1

Y1 - 2019/1

N2 - Objective: Long-acting injectable (LAI) aripiprazole is recommended to be combined with oral aripiprazole for 2 weeks after its introduction. However, we often experience patients who require more than 2 weeks of combined use. Therefore, differences in combination periods need to be examined. Methods: This was a case–control study. We surveyed prescription profiles for oral aripiprazole administration in conjunction with LAI aripiprazole introduction and assessed the clinical course during a 12-week follow-up period. Results: Among 121 patients, 58 (47.9%) were administered both oral and LAI aripiprazole for more than 2 weeks. Although there was no significant difference in treatment failure (defined as psychiatric hospitalization or discontinuation of LAI aripiprazole from any cause) between the two groups, the group that was administered oral aripiprazole for more than 2 weeks received less additional benzodiazepines compared with that of the 2 weeks group (adjusted odds ratio, 0.055; 95% confidence interval [0.0060, 0.50]; p < 0.01). Conclusions: Our data support a flexible co-administration period for oral and LAI aripiprazole in consideration of the pharmacokinetics, but further studies are needed.

AB - Objective: Long-acting injectable (LAI) aripiprazole is recommended to be combined with oral aripiprazole for 2 weeks after its introduction. However, we often experience patients who require more than 2 weeks of combined use. Therefore, differences in combination periods need to be examined. Methods: This was a case–control study. We surveyed prescription profiles for oral aripiprazole administration in conjunction with LAI aripiprazole introduction and assessed the clinical course during a 12-week follow-up period. Results: Among 121 patients, 58 (47.9%) were administered both oral and LAI aripiprazole for more than 2 weeks. Although there was no significant difference in treatment failure (defined as psychiatric hospitalization or discontinuation of LAI aripiprazole from any cause) between the two groups, the group that was administered oral aripiprazole for more than 2 weeks received less additional benzodiazepines compared with that of the 2 weeks group (adjusted odds ratio, 0.055; 95% confidence interval [0.0060, 0.50]; p < 0.01). Conclusions: Our data support a flexible co-administration period for oral and LAI aripiprazole in consideration of the pharmacokinetics, but further studies are needed.

UR - http://www.scopus.com/inward/record.url?scp=85057300555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057300555&partnerID=8YFLogxK

U2 - 10.1002/hup.2681

DO - 10.1002/hup.2681

M3 - Article

C2 - 30480343

AN - SCOPUS:85057300555

VL - 34

JO - Human Psychopharmacology

JF - Human Psychopharmacology

SN - 0885-6222

IS - 1

M1 - e2681

ER -